immunoglobulin G4-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3)] and anti-[Homo sapiens CD274 (programmed cell death 1 ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, PDCD1LG1)], humanized monoclonal antibody, bispecific, bivalent
Acute Myeloid Leukemia
Mabwell (Shanghai) Bioscience Co., Ltd.monoclonal_antibodyPhase 1/2Active
CC
40/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 59/ 100
Competitive context
684 Active assets in the Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gemtuzumab M.D. Anderson Cancer Center | Phase 4 | A |
Cytosin-Arabinosid Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BBB |
AMSACRINE University Hospital, Toulouse | Phase 4 | BBB |
Posaconazole AstraZeneca | Phase 4 | BBB |
(+)-VINCRISTINE Janssen Research & Development, LLC | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
immunoglobulin G4-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3)] and anti-[Homo sapiens CD274 (programmed cell death 1 ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1, B7-H1, PDCD1LG1)], humanized monoclonal antibody, bispecific, bivalent is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →